Stryker Corporation (NYSE:SYK) Shares Bought by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC lifted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 33.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,544 shares of the medical technology company's stock after acquiring an additional 1,142 shares during the period. Fidelis Capital Partners LLC's holdings in Stryker were worth $1,659,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SYK. Elefante Mark B purchased a new stake in Stryker in the 4th quarter worth about $337,000. Mogy Joel R Investment Counsel Inc. increased its position in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after acquiring an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. increased its holdings in Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after buying an additional 3,341 shares during the period. Harbor Capital Advisors Inc. purchased a new position in Stryker during the first quarter valued at approximately $1,840,000. Finally, Fred Alger Management LLC increased its holdings in Stryker by 415.8% during the fourth quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company's stock valued at $8,664,000 after buying an additional 19,356 shares during the period. Institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Truist Financial raised their target price on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research report on Monday, May 5th. Finally, Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $428.55.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Stryker Trading Down 1.4%

NYSE:SYK traded down $5.53 on Friday, hitting $389.24. The stock had a trading volume of 825,133 shares, compared to its average volume of 1,352,494. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The stock has a market cap of $148.57 billion, a price-to-earnings ratio of 52.60, a PEG ratio of 2.98 and a beta of 0.91. The company has a fifty day moving average price of $384.57 and a two-hundred day moving average price of $376.97. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $2.50 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker's payout ratio is currently 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.